DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

NCT04834674 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma
Transarterial Chemoembolization
Apatinib
PD-1 Antibody

Interventions

COMBINATION_PRODUCT: DEB-TACE combined with apatinib and PD-1 antibody

Sponsor

Sichuan Cancer Hospital and Research Institute